As of 2026-09-16, the EV/EBITDA ratio of Denali Therapeutics Inc (DNLI) is -6.39. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. DNLI's latest enterprise value is 3,171.87 mil USD. DNLI's TTM EBITDA according to its financial statements is -496.00 mil USD. Dividing these 2 quantities gives us the above DNLI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-09-04 | -6.73 |
| 2026-09-03 | -6.90 |
| 2026-09-02 | -6.92 |
| 2026-09-01 | -7.05 |
| 2026-08-31 | -7.21 |
| 2026-08-28 | -7.28 |
| 2026-08-27 | -7.50 |
| 2026-08-26 | -7.47 |
| 2026-08-25 | -7.58 |
| 2026-08-24 | -7.35 |
| 2026-08-21 | -7.58 |
| 2026-08-20 | -7.59 |
| 2026-08-19 | -7.83 |
| 2026-08-18 | -7.38 |
| 2026-08-17 | -7.40 |
| 2026-08-14 | -7.41 |
| 2026-08-13 | -7.55 |
| 2026-08-12 | -7.69 |
| 2026-08-11 | -7.51 |
| 2026-08-10 | -7.60 |
| 2026-08-07 | -7.55 |
| 2026-08-06 | -7.52 |
| 2026-08-05 | -7.42 |
| 2026-08-04 | -7.34 |
| 2026-08-03 | -7.01 |
| 2026-07-31 | -6.97 |
| 2026-07-30 | -7.40 |
| 2026-07-29 | -7.24 |
| 2026-07-28 | -7.30 |
| 2026-07-27 | -7.15 |
| 2026-07-24 | -7.00 |
| 2026-07-23 | -7.10 |
| 2026-07-22 | -7.17 |
| 2026-07-21 | -7.23 |
| 2026-07-20 | -6.93 |
| 2026-07-17 | -7.06 |
| 2026-07-16 | -6.88 |
| 2026-07-15 | -6.97 |
| 2026-07-14 | -6.85 |
| 2026-07-13 | -8.08 |
| 2026-07-10 | -7.82 |
| 2026-07-09 | -8.31 |
| 2026-07-08 | -8.15 |
| 2026-07-07 | -8.02 |
| 2026-07-06 | -7.84 |
| 2026-07-02 | -7.87 |
| 2026-07-01 | -7.92 |
| 2026-06-30 | -7.83 |
| 2026-06-29 | -7.89 |
| 2026-06-26 | -7.79 |